FISONS CLASS RECALL OF OPTICROM PRESCRIPTION EYE DROPS involves over 45,000 bottles from two lots of the 4% ophthalmic solution 10 ml bottles, the company announced in a July 13 press release. Evidence of bacterial contamination that could cause serious eye infections in scratched or damaged eyes was found in the two lots of the cromolyn sodium product. The two lots of Opticrom under recall are KF35V, of which 45,223 bottles were distributed, and KF7A, of which 114 bottles were distributed. The recall extends to the consumer level. Distribution was nationwide and included Puerto Rico. The contamination was discovered following tests by Fisons, which manufactures the product in the U.K. The tests "indicated the possible presence of Bacillus cereus in lot KF7A and an unidentified anaerobic bacillus in lot KF35V," the release states. Opticrom is indicated for certain eye allergies, with recommended dosing of one-to-two drops four-to-six times a day. A same-day FDA press release warns that "if patients have a slight scratch on the eye, they are at high risk of developing a potentially sight-threatening infection from a contaminated eye solution."
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Stefan Oelrich, the newly-announced president of European pharma industry federation EFPIA says the EU pharma reform is “not an improvement on the status quo” in its current form.
Oncology trial sponsors in the UK are being invited to participate in a pilot that aims to tackle duplication and variation in pharmacy reviews, which are an important part of setting up clinical trials in the National Health Service.
The new Advisory Committee on Immunization Practices voted for new recommendations on the decades-old thimerosal safety issue and lays intellectual groundwork to revisit other past controversies and decisions.
